Literature DB >> 22925498

Intravesical hyaluronic acid for interstitial cystitis/painful bladder syndrome: a comparative randomized assessment of different regimens.

Ming-Chih Lai1, Yuh-Chen Kuo, Hann-Chorng Kuo.   

Abstract

OBJECTIVES: To compare the clinical effectiveness of different regimens of intravesical hyaluronic acid instillation for patients with interstitial cystitis/painful bladder syndrome.
METHODS: A total of 60 patients (age 16-77 years) diagnosed with interstitial cystitis/painful bladder syndrome were enrolled in this prospective, randomized study. A total of 30 patients were assigned to receive four weekly intravesical instillations of 40 mg of hyaluronic acid followed by five monthly instillations (hyaluronic acid-9 group). Another 30 patients received 12 intravesical instillations of 40 mg hyaluronic acid every 2 weeks (hyaluronic acid-12 group). Symptomatic changes after hyaluronic acid treatments were assessed using Interstitial Cystitis Symptom and Problem Indexes, pain visual analog scale, functional bladder capacity, frequency and nocturia in voiding diary, maximum flow rate, voided volume, postvoid residual volume, and Quality of Life Index at 1, 3 and 6 months.
RESULTS: Of the 60 patients, 59 were evaluable at the end of the study. The Interstitial Cystitis Symptom Index, Interstitial Cystitis Problem Index and total score, pain visual analog scale, functional bladder capacity, maximum flow rate, and Quality of Life Index improved significantly after 6 months in both groups. The frequency and voided volume improved significantly only in the hyaluronic acid-12 group. However, patients with moderate and marked improvement were clinically similar in both groups. The measured variables did not differ between the two groups over the course of the study.
CONCLUSION: No significant difference was noted in the therapeutic effect between two hyaluronic acid instillation regimens for treatment of interstitial cystitis/painful bladder syndrome patients. Both groups showed significant improvement in symptom scores and Quality of Life Index.
© 2012 The Japanese Urological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22925498     DOI: 10.1111/j.1442-2042.2012.03135.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  13 in total

Review 1.  Advances in intravesical therapy for urinary tract disorders.

Authors:  Pradeep Tyagi; Mahendra Kashyap; Harvey Hensley; Naoki Yoshimura
Journal:  Expert Opin Drug Deliv       Date:  2015-10-19       Impact factor: 6.648

2.  Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis.

Authors:  Mari Imamura; Neil W Scott; Sheila A Wallace; Joseph A Ogah; Abigail A Ford; Yann A Dubos; Miriam Brazzelli
Journal:  Cochrane Database Syst Rev       Date:  2020-07-30

3.  [The care situation of patients with interstitial cystitis in Germany: results of a survey of 270 patients].

Authors:  D Jocham; G Froehlich; F Sandig; A Ziegler
Journal:  Urologe A       Date:  2013-05       Impact factor: 0.639

4.  Bladder uptake of liposomes after intravesical administration occurs by endocytosis.

Authors:  Bharathi Raja Rajaganapathy; Michael B Chancellor; Jayabalan Nirmal; Loan Dang; Pradeep Tyagi
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

5.  Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid.

Authors:  Yuan-Hong Jiang; Hsin-Tzu Liu; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

6.  Increased bladder permeability in interstitial cystitis/painful bladder syndrome.

Authors:  Robert E Hurst; Beverley Greenwood-Van Meerveld; Amy B Wisniewski; Samuel VanGordon; HsuehKung Lin; Bradley P Kropp; Rheal A Towner
Journal:  Transl Androl Urol       Date:  2015-10

Review 7.  Novel targeted bladder drug-delivery systems: a review.

Authors:  Martino Maria Zacchè; Sushma Srikrishna; Linda Cardozo
Journal:  Res Rep Urol       Date:  2015-11-23

Review 8.  Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome.

Authors:  Pradeep Tyagi; Mahendra P Kashyap; Naoki Kawamorita; Tsuyoshi Yoshizawa; Michael Chancellor; Naoki Yoshimura
Journal:  ISRN Pharmacol       Date:  2014-01-15

Review 9.  A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis.

Authors:  Jayanta M Barua; Ignacio Arance; Javier C Angulo; Claus R Riedl
Journal:  Int Urogynecol J       Date:  2015-11-20       Impact factor: 2.894

10.  A high molecular weight hyaluronic acid biphasic dispersion as potential therapeutics for interstitial cystitis.

Authors:  Peadar R Rooney; Vijaya Krishna Kannala; Niranjan G Kotla; Ana Benito; Damien Dupin; Iraida Loinaz; Leo R Quinlan; Yury Rochev; Abhay Pandit
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2020-10-26       Impact factor: 3.368

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.